Roy Pettipher
Fondatore presso Orca Pharmaceuticals Ltd.
Profilo
Roy Pettipher is the founder of Orca Pharmaceuticals Ltd.
which was founded in 2012, where he holds the title of Chief Scientific Officer.
He is currently working as a Research Director at Atopix Therapeutics Ltd.
Dr. Pettipher's former positions include Pharmacology Director at Oxagen Ltd., Principal at Pfizer Inc., and Principal at Wellcome Plc.
Posizioni attive di Roy Pettipher
Società | Posizione | Inizio |
---|---|---|
Orca Pharmaceuticals Ltd.
Orca Pharmaceuticals Ltd. BiotechnologyHealth Technology Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom. | Fondatore | 01/01/2012 |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Roy Pettipher
Società | Posizione | Fine |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - |
Wellcome Plc
Wellcome Plc Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK. | Corporate Officer/Principal | - |
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
PFIZER, INC. | Health Technology |
Aziende private | 4 |
---|---|
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Wellcome Plc
Wellcome Plc Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK. | Commercial Services |
Orca Pharmaceuticals Ltd.
Orca Pharmaceuticals Ltd. BiotechnologyHealth Technology Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Roy Pettipher